A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Have histologically or cytologically confirmed advanced or metastatic non-small celllung cancer (NSCLC) that is not amenable to curative intent therapy

• Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858Rsubstitution, as detected by food and drug administration (FDA)-approved or othervalidated test in a clinical laboratory improvement amendments (CLIA)-certifiedlaboratory in accordance with site standard of care

• Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has notbeen previously irradiated

• Any toxicities from prior systemic anticancer therapy must have resolved to nationalcancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or baseline level (except for alopecia [any grade], grade <=2 peripheralneuropathy, or grade <=2 hypothyroidism stable on hormone replacement)

• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion Criteria:

• Medical history of active interstitial lung disease (ILD), including drug-inducedILD or radiation pneumonitis

• Had major surgery excluding placement of vascular access or tumor biopsy or hadsignificant traumatic injury within 4 weeks before the first dose of anticancertreatments or will not have fully recovered from surgery, or has surgery plannedduring the time the participant is expected to participate in the study

• Participant has uncontrolled tumor-related pain (symptomatic lesions amenable topalliative radiotherapy should be treated prior to first dosing)

• Received an investigational treatment that has not been cleared (based on at least 5half lives of any pharmaceutical treatment) or within 12 months before the plannedfirst dose of study treatment or is currently enrolled in an investigational study

• Has a prior or concurrent second malignancy (other than the disease under study)which natural history or treatment could likely interfere with any study endpointsof safety or the efficacy of the study treatment(s)